Core Viewpoint - Levi & Korsinsky, LLP has initiated a class action securities lawsuit on behalf of investors in Cassava Sciences, Inc. due to alleged securities fraud impacting the company's stock performance [2][3]. Group 1: Lawsuit Details - The lawsuit targets losses incurred by Cassava Sciences, Inc. investors from February 7, 2024, to November 24, 2024, related to alleged securities fraud [3]. - The complaint alleges that defendants misled investors regarding the efficacy of Cassava's drug candidate, simufilam, particularly in treating Alzheimer's Disease [4]. - Following the release of disappointing Phase 3 study results for simufilam on November 25, 2024, the stock price plummeted from $26.48 to $4.30, marking a decline of approximately 83.76% in one day [4]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until February 10, 2025, to request appointment as lead plaintiff in the lawsuit [5]. - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [5].

NEW YORK, Dec. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=118159&from=4CLASS PERIOD: Februar ...

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

Core Viewpoint - The article discusses a class action lawsuit against Cassava Sciences, Inc. (NASDAQ: SAVA) following the disappointing results of its Alzheimer's drug candidate, simufilam, which led to a significant drop in the company's stock price [2][4]. Group 1: Allegations and Stock Performance - The complaint alleges that defendants provided misleading information regarding simufilam's efficacy in treating Alzheimer's Disease, expressing confidence in its performance [2]. - On November 25, 2024, Cassava announced that simufilam failed to meet all primary, secondary, and exploratory endpoints in its Phase 3 "ReThink-ALZ" study, underperforming against a placebo [2]. - Following the announcement, Cassava's stock plummeted from $26.48 per share on November 22, 2024, to $4.30 per share on November 25, 2024, marking a decline of approximately 83.76% in just one day [2]. Group 2: Next Steps for Shareholders - Shareholders who purchased SAVA shares during the specified class period (February 7, 2024, to November 24, 2024) are encouraged to register for potential lead plaintiff appointment, with a deadline set for February 10, 2025 [3][5]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, with no cost or obligation to participate [3].

NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Cassava and certain of its offic ...

NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ps ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cassava To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Dec. 18, 2024 /PRNewswi ...

NEW YORK, Dec. 17, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ps ...

SAN DIEGO, Dec. 16, 2024 /PRNewswire/ -- Robbins LLP announces that a class action was filed on behalf of all investors who purchased or otherwise acquired Cassava Sciences, Inc. (NASDAQ: SAVA) securities between February 7, 2024 and November 24, 2024. Cassava is a clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Invest ...

NEW YORK, Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=116401&from=4CLASS PERIOD: Februar ...